Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.
The failed Checkmate-651 study hints at a survival benefit in some PD-L1 expressers, but will this be enough to file?
Glaxo’s anti-PD-1 MAb might not have a market niche to itself for long, while a separate trial could help Keytruda double its adjuvant melanoma potential.
Full data from the Poseidon study confirm the anti-CTLA-4 MAb’s activity; with three chemo combos established, however, will it be enough?
Rilzabrutinib flunks a pivotal trial in pemphigus, but all eyes are on tolebrutinib in multiple sclerosis.
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.
The US regulator’s restrictions spell trouble for the Jak inhibitor class – though there will be beneficiaries.
July and August saw key regulatory and clinical developments for several anti-PD-(L)1 MAbs, with plenty more in store for oncology watchers.